Clinical Trial Update: Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for the PET radiotracer MK-3328 ([18F]MK3328) assessing safety, radiation dosimetry, biokinetics, and effectiveness in Alzheimer's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [18F]MK3328 (MK-3328)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2014-02-05